We hypothesise that elevated EIF4E levels promote HER2‐negative breast cancer cell proliferation, migration and invasion by regulating molecules associated with Wnt signalling and ECM components, thereby contributing to disease progression and poorer patient outcomes. Here, EIF4E is linked to breast carcinoma.